The funding for the grant is focused on providing collaboration with institutions outside of academia. This is to insure that the results have external validation and will be well accepted by industry and investors.
“… 50% of the studies published even in top tier academic journals – Science, Nature, Cell, PNAS, etc… – can’t be repeated with the same conclusions by an industrial lab.” – Bruce Booth, Atlas Ventures. If the findings can be validated in a trusted contract research, the prospects for funding would increase significantly.
No, the funding may provide data to submit provisional or to convert. However, an initial assessment of patentable opportunity will be required.
The goal of this funding is to provide resources to those innovations that are not already supported. If there are encumbrances, the project may be too advanced for this funding.
Any faculty member or researcher interested or involved in translation activities.
A “CRO” is a Contract Research Organization. It performs research and development services for the pharmaceutical, biotechnology, and medical device industries. These research and development activities conform to industry and regulatory standards.
The types of experiments typically run by a CRO are done in large volume against experimental and historical controls and are not the sorts of experiments typically performed in an academic setting. For example, GLP conditions (e.g., ADME, Tox, and models that are frequently different from the ones used in an academic setting) or those models used in academic settings, but using N’s and additional arms, duration, etc., that are beyond the scope or affordability of the typical academic lab. Data can be used to support regulatory filings.
Blavatnik funding is designed to augment and leverage results from PITCH, EVOTEC, CBIT, etc.
The Blavatnik Investment Advisory Board was established with individuals who are top leaders in running and investing in successful life sciences companies across the country. The board was formed with the support of the Provost to provide decisions on investments for the fund. All members have deep technical expertise in the life sciences (PhDs, MDs), extensive business background and strong connections to Yale. They are committed to supporting Yale faculty and researchers to advance their technologies to the market.
The multi-year grant will support the Blavatnik Fund for Innovation at Yale and is designed to bridge the gap between life sciences research and business and to accelerate the commercialization of groundbreaking, investigator-initiated discoveries. The grant also establishes the Blavatnik Fellows Program, giving a select group of young professionals access to Yale researchers, as well as inventors, venture capitalists, and business leaders, who will provide the fellows with the technical and business skills needed to become the next generation of leaders in scientific entrepreneurship.
The funding will be split over the course of five years to support translational life-science. As this is the first year of the fund the number depends on the type of funding required and projects submitted. There are two types of awards- Pilot ($25k-$100k) and Development ($200k-$300k). The Board will work closely to advance as many projects (estimated 5-10) as possible that have significant opportunities for partnership and additional external investment.
Any Yale faculty member or researcher that is obligated to assign IP to Yale and highly committed to having his/her innovations developed and commercialized.
Maybe - If your technology/application is already licensed or obligated to a corporate entity we will need to evaluate the fit. We are looking for opportunities where this funding does not yet exist and will advance ideas to sponsored research, corporate partnerships or venture investment. However, if you have a different application for your technology – we look forward to exploring the fit with you.
Please send an email to firstname.lastname@example.org with a few lines about your project, your interest and your name/contact information. We will follow up with all requests within two days to set up a meeting and provide additional guidance.
Technologies that will be considered include therapeutics, medical devices, diagnostics and life-science platform technologies. Health care IT will not be considered at this time.
Yes, provided the company has licensed Yale IP and has had little to no funding (i.e no venture capital investment).